Critical Analysis: Intra-Cellular Therapies, Inc. v. Controller of Patents (2026:DHC:5394) C.A.(COMM.IPD-PAT) 24/2023 | Delhi High Court | Decided: 06.07.2026 I. Doctrinal Analysis: Novelty and the "Coverage vs. Disclosure" Question A. The genus-species anticipation problem The core novelty dispute was a classic Markush-genus-versus-species-selection issue. The appellant argued that arriving at the claimed species from the generic Formula I of D1/D7 required " multiple selections " among independent variables (R1–R6), and that the Controller impermissibly relied on more than one prior art document to construct a single "closest prior art" novelty attack — a submission with real doctrinal pedigree, since novelty (unlike obviousness) is ordinarily tested against a single prior document read as a whole. The Court's response — invoking AstraZeneca AB and Boehringer Ingelheim v. Vee Excel — collapses the " covered vs. disclosed " dist...
Effective June 1, 2026, the Jan Vishwas (Amendment of Provisions) Act, 2026 has introduced significant reforms to Chapter XX of the Patents Act, 1970. These amendments represent a pivotal shift in how India balances patent compliance obligations with ease of doing business. Rather than introducing sweeping new regulations, the amendments refine existing provisions, reflecting a measured approach to modernizing India's patent enforcement landscape while maintaining robust protections for sensitive inventions. This article examines the three primary amendments, their immediate implications, and the strategic considerations they impose on patent stakeholders across India. Part I: The Amendments Explained 1. Semantic Reframing: From Penalties to Punishments The Change: Old Heading: "Penalties" New Heading: "Punishments" What This Means: The decision to replace "Penalties" with "Punishments" is far more than cosmetic nomenclat...